Experts share how much sleep teenagers need and why. Plus, tips to help teens sleep better.
The FDA expanded the indication of the long-acting growth hormone somapacitan (Sogroya) to include very young children with idiopathic short stature, short stature born small for gestational age, or ...
FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.
It joins the CNP analog vosoritide (Voxzogo), a once-daily injection, as the only treatments approved for achondroplasia. Other treatments include growth hormone injections, limb-lengthening surgery, ...
Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.
Few topics provoke as much concern as the perception that puberty is beginning earlier than ever. While synthetic ...
Novo Nordisk A/S (NYSE:NVO) is one of the best cheap stocks under $50 to buy right now. Novo Nordisk A/S (NYSE:NVO) announced ...
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for ...
Novo Nordisk received approval from the Food and Drug Administration for three new indications of Sogroya, a growth hormone.
The boy’s father, Arturo Bazan, adoptive mother Dulce Bazan and older brother Carlos Hernandez-Bazan, 25, are charged with child abuse and torture.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results